
|Videos|September 15, 2017
Remaining Questions With Multiple Myeloma Treatment
Author(s)Robert Orlowski, MD, PhD
Robert Orlowski, MD, PhD, Florence Maude Thomas Cancer Research professor and chair, ad interim, Department of Lymphoma & Myeloma at The University of Texas MD Anderson Cancer Center, discusses remaining questions with multiple myeloma treatment.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Patient Case #2: Newly Diagnosed Stage 3B NSCLC
2
Remaining Unmet Needs in Biomarker Testing in Early-stage NSCLC
3
Elraglusib Combo Yields Notable 24-Month Survival Benefit in Metastatic PDAC
4
Multi-Trial Analysis Reveals Disconnect Between PFS and OS in Ovarian Cancer
5














































